226 related articles for article (PubMed ID: 28883518)
1. New compounds identified through in silico approaches reduce the α-synuclein expression by inhibiting prolyl oligopeptidase in vitro.
Kumar R; Bavi R; Jo MG; Arulalapperumal V; Baek A; Rampogu S; Kim MO; Lee KW
Sci Rep; 2017 Sep; 7(1):10827. PubMed ID: 28883518
[TBL] [Abstract][Full Text] [Related]
2. Investigation of novel chemical scaffolds targeting prolyl oligopeptidase for neurological therapeutics.
Kumar R; Parameswaran S; Bavi R; Baek A; Son M; Rampogu S; Park C; Lee G; Zeb A; Parate S; Rana RM; Lee KW
J Mol Graph Model; 2019 May; 88():92-103. PubMed ID: 30665156
[TBL] [Abstract][Full Text] [Related]
3. Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors.
Babkova K; Korabecny J; Soukup O; Nepovimova E; Jun D; Kuca K
Future Med Chem; 2017 Jun; 9(10):1015-1038. PubMed ID: 28632451
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous (19)F NMR screening of prolyl oligopeptidase and dipeptidyl peptidase IV inhibitors.
Kichik N; Tarragó T; Giralt E
Chembiochem; 2010 May; 11(8):1115-9. PubMed ID: 20397181
[TBL] [Abstract][Full Text] [Related]
5. Targeted Covalent Inhibition of Prolyl Oligopeptidase (POP): Discovery of Sulfonylfluoride Peptidomimetics.
Guardiola S; Prades R; Mendieta L; Brouwer AJ; Streefkerk J; Nevola L; Tarragó T; Liskamp RMJ; Giralt E
Cell Chem Biol; 2018 Aug; 25(8):1031-1037.e4. PubMed ID: 29779956
[TBL] [Abstract][Full Text] [Related]
6. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.
Myöhänen TT; Norrbacka S; Savolainen MH
Neurosci Lett; 2017 Jan; 636():83-89. PubMed ID: 27818354
[TBL] [Abstract][Full Text] [Related]
7. Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).
Haffner CD; Diaz CJ; Miller AB; Reid RA; Madauss KP; Hassell A; Hanlon MH; Porter DJ; Becherer JD; Carter LH
Bioorg Med Chem Lett; 2008 Aug; 18(15):4360-3. PubMed ID: 18606544
[TBL] [Abstract][Full Text] [Related]
8. Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells.
De Cesco S; Deslandes S; Therrien E; Levan D; Cueto M; Schmidt R; Cantin LD; Mittermaier A; Juillerat-Jeanneret L; Moitessier N
J Med Chem; 2012 Jul; 55(14):6306-15. PubMed ID: 22765237
[TBL] [Abstract][Full Text] [Related]
9. Constrained peptidomimetics reveal detailed geometric requirements of covalent prolyl oligopeptidase inhibitors.
Lawandi J; Toumieux S; Seyer V; Campbell P; Thielges S; Juillerat-Jeanneret L; Moitessier N
J Med Chem; 2009 Nov; 52(21):6672-84. PubMed ID: 19888757
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide.
Racys DT; Rea D; Fülöp V; Wills M
Bioorg Med Chem; 2010 Jul; 18(13):4775-82. PubMed ID: 20627594
[TBL] [Abstract][Full Text] [Related]
11. Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions.
Jarho EM; Wallén EA; Christiaans JA; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J; Poso A
J Med Chem; 2005 Jul; 48(15):4772-82. PubMed ID: 16033257
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel Trypanosoma cruzi prolyl oligopeptidase inhibitors by structure-based virtual screening.
de Almeida H; Leroux V; Motta FN; Grellier P; Maigret B; Santana JM; Bastos IM
J Comput Aided Mol Des; 2016 Dec; 30(12):1165-1174. PubMed ID: 27770305
[TBL] [Abstract][Full Text] [Related]
13. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers.
Dokleja L; Hannula MJ; Myöhänen TT
Neurosci Lett; 2014 Nov; 583():37-42. PubMed ID: 25240592
[TBL] [Abstract][Full Text] [Related]
15. Oligopeptidase B and B2: comparative modelling and virtual screening as searching tools for new antileishmanial compounds.
Sodero AC; Dos Santos AC; Mello JF; DE Jesus JB; DE Souza AM; Rodrigues MI; DE Simone SG; Rodrigues CR; DE Matos Guedes HL
Parasitology; 2017 Apr; 144(4):536-545. PubMed ID: 28031079
[TBL] [Abstract][Full Text] [Related]
16. Benzimidazolium salts as small, nonpeptidic and BBB-permeable human prolyl oligopeptidase inhibitors.
Tarragó T; Masdeu C; Gómez E; Isambert N; Lavilla R; Giralt E
ChemMedChem; 2008 Oct; 3(10):1558-65. PubMed ID: 18792035
[TBL] [Abstract][Full Text] [Related]
17. A new side opening on prolyl oligopeptidase revealed by electron microscopy.
Tarragó T; Martín-Benito J; Sabidó E; Claasen B; Madurga S; Gairí M; Valpuesta JM; Giralt E
FEBS Lett; 2009 Oct; 583(20):3344-8. PubMed ID: 19782684
[TBL] [Abstract][Full Text] [Related]
18. Structure-based virtual screening for novel chymase inhibitors by in silico fragment mapping.
Ozawa SI; Takahashi M; Yamaotsu N; Hirono S
J Mol Graph Model; 2019 Jun; 89():102-108. PubMed ID: 30884446
[TBL] [Abstract][Full Text] [Related]
19. Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods.
Kulkarni AM; Kumar V; Parate S; Lee G; Yoon S; Lee KW
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163234
[TBL] [Abstract][Full Text] [Related]
20. Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein.
Brandt I; Gérard M; Sergeant K; Devreese B; Baekelandt V; Augustyns K; Scharpé S; Engelborghs Y; Lambeir AM
Peptides; 2008 Sep; 29(9):1472-8. PubMed ID: 18571285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
